Bioorganic ChemistryBioengineeringPeer-reviewed journal article
BACH1 promotes hepatocellular carcinoma progression by targeting PDP1 towards the PI3K-AKT-mTOR signaling activation
Qiqi Bu, Xiaojing Qi, Qing WangiD, Shujuan LiuiD, Shanshan LiniD, Zhanhang Wang, Yiguo ZhangiD
Abstract
Hepatocellular carcinoma (HCC) is remaining to be accepted as a major challenge against public health, because of its high incidence and mortality. Herein, we explored underlying molecular mechanisms by which BTB and CNC homology 1 (BACH1) facilitated progression of HCC. Functional experiments indicated that BACH1 promoted the proliferation, clonogenicity, cycle progression of HCC cells, and inhibited apoptosis. Knockout of BACH1 decreased mitochondrial membrane potential, augmented reactive oxygen species (ROS) generation, induced cell apoptosis, and reduced malignant growth of xenograft neoplasms in mice. Mechanistic experiments revealed that BACH1 bound to the ARE sites in the promoter region of pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1), so to activate its transcriptional expression and promote cellular energy metabolism. Interestingly, BACH1 enables activation of the cell growth-related TGF-{beta}1/SMAD signaling pathway, which further promoted the malignant proliferation of HCC cells. Of note, PDP1 functions as a tumor promoter, since lowering its expression levels suppressed the clonogenicity in HCC cells. Furthermore, such downregulation in BACH1 or PDP1 could inhibit the PI3K-AKT-mTOR signaling. In conclusion, these reveal that BACH1 manifests a dominant tumor-promoting factor and is hence viewed as a promising therapeutic target of HCC, because it promotes HCC progression by targeting PDP1 towards PI3K-AKT-mTOR pathway activation.
- organism: human
- research focus: cancer & tumor microenvironment
- research focus: gene regulatory network inference
- research focus: differential expression
- approach: experimental assay
- Citations
- 4
- FWCI
- 1.20
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Occurrence of Biased mTOR Signaling in Hepatocellular Carcinoma
Rudransh Singh, Niriksha Patel, … Sunil Shetty·bioRxiv·Jul 26, 2026
- Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing Aldob/Akt/PP2A protein complex
- HKDC1 Promotes Liver Cancer Stemness Under Hypoxia via Stabilizing β-Catenin
- The hexokinase ''HKDC1'' interaction with the mitochondria is essential for hepatocellular carcinoma progression
M. W. Khan, A. Terry, … B. T. Layden·bioRxiv·Nov 10, 2021
- Comprehensive Network of Signaling Pathways in Hepatocellular Carcinoma and Network Analysis Reveals PTK2, GSK3β, and β-catenin to be Crucial for Cancer Progression
Sai Bhavani Gottumukkala, Akilan Malaieaswaran, Anbumathi Palanisamy·bioRxiv·Jul 25, 2025
- AMPK activation prevents HCC development through inhibition of HNF4a activity
Zhen Sun, Bernard Linares, … Jeanine L. Van Nostrand·bioRxiv·May 16, 2025